NCT06406465 2026-03-18
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT02595424 2025-12-29
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04268121 2025-07-23
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT05913427 2024-08-01
PESETA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Recruiting
NCT00193531 2023-04-11
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03963193 2019-05-24
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Henan Cancer Hospital
Phase 2 Unknown
NCT00001339 2008-03-04
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
National Institutes of Health Clinical Center (CC)
Phase 2 Completed